januar 29, 2019
Advancing FUROSCIX® with the SmartDose® Drug Delivery System – Forecast 2018 year-end cash of $82 – $87 million and 2019 expenditures of $8 – $10 million per quarter BURLINGTON, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of...
CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, announced today that it has initiated a Phase 1 clinical trial of SPR720, an orally administered antimicrobial agent being developed for the treatment of non-tuberculous mycobacterial (NTM)...
Cambridge, UK and Indianapolis, US – 28 January 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) welcomes an editorial published in the leading peer-reviewed journal Anesthesiology, accompanying the print publication of results from its positive Phase 3 clinical trial of BARHEMSYS™ (intravenous amisulpride) as rescue treatment of established post-operative nausea & vomiting...


Fem unge medicinstuderende på forskningsophold i USA
9. juli 2020
Lundbeckfonden Ventures investerer i antidot mod blodfortyndere
8. juli 2020
Erfaren hjerneforsker i spidsen for The Brain Prize
30. juni 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge